← Back to Screener
Tango Therapeutics, Inc. (TNGX)
Price$26.39
Favorite Metrics
Price vs S&P 500 (26W)264.36%
Price vs S&P 500 (4W)27.68%
Market Capitalization$3.80B
All Metrics
Book Value / Share (Quarterly)$2.55
P/TBV (Annual)3.08x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)35.89%
Cash Flow / Share (Quarterly)$-1.03
Price vs S&P 500 (YTD)196.54%
Net Profit Margin (TTM)-151.15%
EPS (TTM)$-0.87
10-Day Avg Trading Volume2.83M
EPS Excl Extra (TTM)$-0.87
EPS (Annual)$-0.87
ROI (Annual)-65.15%
Net Profit Margin (5Y Avg)-268.70%
Cash / Share (Quarterly)$2.52
Revenue Growth QoQ (YoY)363.61%
ROA (Last FY)-41.23%
Revenue Growth TTM (YoY)48.29%
EBITD / Share (TTM)$-0.89
ROE (5Y Avg)-33.14%
Operating Margin (TTM)-165.91%
Cash Flow / Share (Annual)$-1.22
P/B Ratio10.98x
P/B Ratio (Quarterly)3.45x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)55.47x
ROA (TTM)-36.25%
EPS Incl Extra (Annual)$-0.87
Current Ratio (Annual)7.00x
Quick Ratio (Quarterly)15.85x
3-Month Avg Trading Volume3.20M
52-Week Price Return1981.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
P/S Ratio (Annual)60.93x
Asset Turnover (Annual)0.13x
52-Week High$26.81
Operating Margin (5Y Avg)-288.19%
EPS Excl Extra (Annual)$-0.87
26-Week Price Return273.11%
Quick Ratio (Annual)6.78x
13-Week Price Return115.01%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.32x
Enterprise Value$3,688.952
Asset Turnover (TTM)0.26x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-162.85%
Cash / Share (Annual)$2.39
3-Month Return Std Dev101.56%
Net Income / Employee (TTM)$-1
ROE (Last FY)-65.15%
EPS Basic Excl Extra (Annual)$-0.87
Receivables Turnover (TTM)36.53x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.87
Receivables Turnover (Annual)12.43x
ROI (TTM)-50.30%
P/S Ratio (TTM)57.16x
Pretax Margin (5Y Avg)-268.32%
Revenue / Share (Annual)$0.54
Tangible BV / Share (Annual)$2.83
Price vs S&P 500 (52W)1946.16%
Year-to-Date Return200.68%
5-Day Price Return23.56%
EPS Normalized (Annual)$-0.87
ROA (5Y Avg)-20.59%
Net Profit Margin (Annual)-162.85%
Month-to-Date Return27.34%
Cash Flow / Share (TTM)$-1.08
EBITD / Share (Annual)$-0.90
Operating Margin (Annual)-178.39%
ROI (5Y Avg)-33.14%
EPS Basic Excl Extra (TTM)$-0.87
P/TBV (Quarterly)2.78x
P/B Ratio (Annual)1.67x
Pretax Margin (TTM)-150.99%
Book Value / Share (Annual)$1.84
Price vs S&P 500 (13W)112.15%
Beta1.39x
Revenue / Share (TTM)$0.47
ROE (TTM)-50.30%
52-Week Low$1.03
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.29
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TNGXTango Therapeutics, Inc. | 57.16x | 48.29% | — | — | $26.39 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Tango Therapeutics is a precision oncology company developing novel targeted therapies for cancer. The company is advancing PRMT5 inhibitors including TNG462 for non-CNS cancers such as pancreatic and lung cancer, and TNG456, a brain-penetrant inhibitor for CNS cancers including glioblastoma. The pipeline also targets CoREST pathways.